---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-23-000004"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:22:26.226894+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q2 net loss $18.6M; cash $137.8M; CEO transition to Stephen Uden

## Summary
- Net loss $18.6M ($0.46/sh) vs $17.6M ($0.57/sh) in Q2 2022; R&D expense $13.1M, up from $10.1M.
- Cash, equivalents and marketable securities $137.8M as of June 30, providing runway into 1Q 2025.
- RLYB212 Phase 1b proof-of-concept met endpoint; multiple-dose cohort data and tox results expected in 4Q 2023.
- RLYB116 Phase 1 MAD study initial data (safety, PK, PD) and indication strategy expected in 4Q 2023.
- Effective Aug 1, Stephen Uden became CEO; Martin Mackay appointed Executive Chairman.

## SEC filing metadata
- accession: 0001739410-23-000004
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/0001739410-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/rlyb-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-23-000004
- JSON: https://secwatch.observer/filing/0001739410-23-000004.json
- Plain text: https://secwatch.observer/filing/0001739410-23-000004.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported the second quarter ended June 30, 2023 results: net income Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46, EPS $0.46.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss was $18.6 million for the second quarter of 2023, or net loss per common share of $0.46
  - EPS: $0.46
  - Result: reported results
  source text: On August 8, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/0001739410-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.